Kwang-ho Cheong

Title: **Kwang-ho Cheong: Pioneering Advances in Cancer Treatment**

Introduction: Kwang-ho Cheong, an accomplished inventor based in Seoul, South Korea, has made significant contributions to the field of biomedical innovations. With a total of eight patents to his name, Cheong’s work focuses on antibody technologies that target cancer treatment.

Latest Patents: Among his most recent patents is an invention titled “Antibody specifically binding to epitope in SEMA domain of c-Met.” This patent describes an antibody or antigen binding fragment that targets a specific epitope in the SEMA domain of the c-Met protein. It also includes pharmaceutical compositions, methods, kits, nucleic acids, and cells related to this technology. Another notable patent is for “Deimmunized anti c-Met humanized antibodies and uses thereof,” which encompasses a deimmunized anti c-Met humanized antibody, a pharmaceutical composition featuring this antibody, and methods for the prevention and treatment of cancer.

Career Highlights: Kwang-ho Cheong is currently employed at Samsung Electronics Co., Ltd., where he continues to innovate in the realm of biopharmaceuticals. His research and development efforts are at the forefront of creating novel therapies that target cancer cells effectively.

Collaborations: Throughout his career, Cheong has collaborated with esteemed colleagues such as Seung-Hyun Lee and Sang-hyun Paek. These partnerships have played a crucial role in advancing their shared goals of developing cutting-edge medical solutions.

Conclusion: Kwang-ho Cheong exemplifies the spirit of innovation in the medical field. His work on antibody technologies and collaborations with researchers highlight his commitment to improving cancer treatment and patient outcomes. As he continues to contribute to the biomedical landscape, the impact of his inventions is poised to offer hope to many affected by cancer.